Adjunctive steroids for reducing residual pleural effusion in patients CITATION Fleishman SI, Coetzee AM, Mindel S, Berjak J, Lichter AI. Antituberculous therapy combined with adrenal steroids in the treatment of pleural effusions: a controlled therapeutic trial. Lancet. 1960 Jan 23;1:199-201 RESEARCH QUESTION Compared to standard therapy, how effective is adjunctive steroid therapy for treating patients with pleural effusion of unknown cause? THE STUDY Controlled therapeutic trial. STUDY SETTING Central hospital within the mining area of Witwatersrand, Johannesburg. PARTICIPANTS Included:
Mineworkers with pleural effusion of unknown cause, presumably all men.
Patients with Pulmonary Tuberculosis (TB), other TB, adenopathy, abdominal masses, vitamin deficiency, bilateral effusions.
INTERVENTIONS
1. Treatment V: Ascorbic Acid 500mg IM daily for 14 days 2. Treatment P: Procaine Penicillin 300,000 units IM twice daily for 14 days 3. Treatment T: ATT (see below) 4. Treatment TS: ATT plus corticosteroids (see below)
ATT Plus Description Frequency
3 times daily, then 3 times daily for rest of 8 weeks
Duration
for 2 days at higher dose, rest of 8 weeks at lower dose
Co-interventions: OUTCOMES Primary:
Reduction in the extent of pleural effusion
Are scurvy and pneumonia involved in the pathogenesis of pleurisy?
RISK OF BIAS SELECTION BIAS: moderate to high Previously prepared sealed instructions of treatment. As each case was admitted to the trial, hospital clerical staff drew one so that the treatment was allocated at random. Table 1: Appears to be balanced for Initial weights and Initial ESR. However no other parameters (e.g. demographics) are reported on. The ESR appears to be low for TB for which you would normally expect readings of around 40+ mm/hr. PERFORMANCE BIAS: low (ie: What else happened that may have affected the result?) Patients not blinded - Not a problem since outcome is not affected by patient’s performance. Patients were confined to hospital – good compliance to therapy Period of bed rest varied according to “patient’s condition” – article did not clarify who made this judgement. Initial aspiration of 20 ml of pleural fluid may affect first four weeks’ score. DETECTION BIAS: low Pleural effusions were scored by a panel of 5 doctors who, according to the authors, were blinded to the patient's treatment. No indication that the laboratory staff was blinded. However, it appears as if the panel were aware of the treatment given at the beginning of the trial since on page 200, column 2 – "this result became known only at the completion of his course of treatment" almost indicating that they would have changed the treatment had they known? ATTRITION BIAS: No intention to treat analysis performed. Total STUDY FINDINGS Significant reduction in the extent of the effusion in TS at 4 weeks No significant reduction seen from 4 weeks to 8 weeks PRESENCE OF RESIDUAL FLUID (95% CI) Treatment
ADVERSE EVENTS Four patients deteriorated: Treatment change from V, P to T, TS COMMENTS Adjunctive steroid therapy appears to be an effective treatment for reducing residual pleural fluid in patients with pleural effusion of unknown cause. Prepared by: MARK ENGEL E-mail:
AVAILABLE DOSSIERS - Approved in at least one EU countryLyophilised powder for solution for infusion in glass vial Acyclovir Concentrate for solution for infusion in plastic ampoule blow-fill-seal Amoxicillin/Clavulanic acid Powder for solution for injection in glass vial Cefepime Powder for solution for injection in glass vial Cefonicid Powder and solvent for solution for
55. Al drieduizend jaar en meer is deze ziekte dus bij artsen bekend. En al drieduizend jaar en meer klopt de mensheid op de deur van de arts en vraagt om genezing. - Fortune, maart I937Nu is het de beurt aan kanker om een ziekte te worden die niet klopt voor hij ergens naar binnen gaat. Susan Sontag, Illness as Metaphor 56. Kanker daarentegen heeft een veel moderner imago. De kankercel is een d